Thursday, 15 October 2026European Markets

BLEECKER Stock Bearish Momentum With A 15% Slide In The Last 5 Sessions

Loading stream...

(vianews) - shares of bleecker (cac 40: blee.pa) dropped by a staggering 15.66% in 5 sessions from €198.01 to €167.00 at 14:52 est on monday, after five consecutive sessions in a row of losses. cac 40 is falling 1.3% to €7,278.86, after five sequential sessions in a row of gains.

bleecker's last close was €166.00, 27.83% under its 52-week high of €230.00.

about bleecker

bleecker société anonyme, a property company, operates in the real estate sector in france. the company develops and manages industrial premises, offices, and logistics platforms. as of august 31, 2010, it had 26 properties or property complexes covering a surface area of 208,228 square meters. the company is based in paris, france.

earnings per share

as for profitability, bleecker has a trailing twelve months eps of €-11.49.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.04%.

yearly top and bottom value

bleecker's stock is valued at €167.00 at 14:52 est, way below its 52-week high of €230.00 and above its 52-week low of €157.00.

more news about bleecker (blee.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com